Esperion Therapeutics
ESPR
ESPR was delisted on the 10th of July, 2026.
102 hedge funds and large institutions have $148M invested in Esperion Therapeutics in 2016 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 43 increasing their positions, 28 reducing their positions, and 18 closing their positions.
54% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 28
6% less funds holding
Funds holding: 109 → 102 (-7)
15% less call options, than puts
Call options by funds: $1.25M | Put options by funds: $1.48M
33% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 18
45% less capital invested
Capital invested by funds: $268M → $148M (-$121M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VOYA Investment Management
Atlanta,
Georgia
|
+$4.95M |
| 2 |
DCM
Discovery Capital Management
South Norwalk,
Connecticut
|
+$4.04M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$3.84M |
| 4 |
SAM
Senzar Asset Management
New York
|
+$3.64M |
| 5 |
FMA
FNY Managed Accounts
New York
|
+$3.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCI
Columbus Circle Investors
|
-$18.9M |
| 2 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
-$10.7M |
| 3 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$3.74M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$3.57M |
| 5 |
ARTA
A.R.T. Advisors
New York
|
-$2.94M |
ESPR Hedge Fund Activity: Q2 2016 in Review
102 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Esperion Therapeutics (ESPR) for Q2 2016, worth a combined $148M — down 45% from $268M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of ESPR and 12 opened new positions — a net loss of 6 holders — while 28 trimmed existing stakes and 43 added.
The largest buyer was VOYA Investment Management, adding an estimated $4.95M. The largest seller was Columbus Circle Investors, exiting entirely with an estimated $18.9M sold.
- 102 institutional investors held Esperion Therapeutics (ESPR) as of Q2 2016, down from 109 in Q1 2016.
- Funds reported $148M of Esperion Therapeutics stock for Q2 2016, down 45% quarter-over-quarter.
- 12 funds opened new Esperion Therapeutics positions in Q2 2016 and 18 closed out, a net change of -6 holders.
- The largest Esperion Therapeutics buyer in Q2 2016 was VOYA Investment Management, an estimated $4.95M added.
- The largest Esperion Therapeutics seller in Q2 2016 was Columbus Circle Investors, an estimated $18.9M sold.
Based on aggregated 13F filings for Q2 2016.